Instem, a leading provider of IT
solutions to the global early development healthcare market,
announced today that Simbec
Research ("Simbec") has purchased the ALPHADAS®
clinical trials software solution suite for deployment in its UK-based
Phase I unit.
Founded in 1976, Simbec
is one of Europe's leading contract research organizations specializing
in early clinical research services for the international pharmaceutical
industry. Simbec has conducted over 1,500 early phase clinical studies;
created, planned and managed within a wide range of therapeutic areas.
In addition to its comprehensive functionality, Simbec selected Instem's ALPHADAS
software suite due to its proven reputation for quality and performance
among the world's leading research organizations. ALPHADAS is the
standard for early phase systems used by organizations across four
continents to improve client efficiencies, reduce trial times and
provide real-time data to sponsors.
"Part of Simbec's market evaluation was a month long trial versus
another system which gave them the focused testing environment to fully
compare the systems," comments Mark Cusack, VP Business Development at
Instem Clinical. "ALPHADAS being favoured in this competitive comparison
was further supported by our peerless track record of delivery and
success. The fact that ALPHADAS can be deployed 'out of the box' to meet
Simbec's requirements coupled with the significant additional value to
their clients means ALPHADAS will deliver an immediate return on
investment for Simbec, and prove a clear competitive distinction."
Simbec has been experiencing strong growth and now supported by the
investment from the newly created £100m WLSIF fund, which is managed by
Professor Sir Christopher Evans' Arthurian, Simbec's selection of
ALPHADAS and the global Instem organization is a strong and highly
Instem's ALPHADAS software solution suite is a proactive eSource
clinial research and early phase trials system that is mobile,
schedule-driven, and provides real-time bedside or station based direct
data capture that virtually eliminates paper-based data.
"We are looking forward to establishing a long term partnership with
Instem, and knowing how closely they collaborate with clients gives us
the confidence that ALPHADAS will help us deliver the next level of
research excellence and uncompromised standards of quality," states Dr.
Trevor Tanner, Director of Scientific Affairs at Simbec.
About Simbec Research
Founded in 1976 with a small team of researchers from the UK National
Health Service, Simbec Research is now one of Europe's leading contract
research organizations specializing in early clinical research services
for the international pharmaceutical industry. Simbec has a stellar
track record for safety and compliance in Phase I/IIa project delivery
to the pharmaceutical and biotechnology industries. Simbec additionally
provides a wide range of services for bioequivalence studies and its
Central Laboratory Service, with fully GLP and GCP compliant
laboratories, is accredited by the CPA (UK).
More about Simbec can be found at www.simbec.com
Instem is a leading supplier of IT applications to the early development
healthcare market delivering compelling
solutions for data collection, management and analysis across the
R&D continuum. Instem applications are in use by customers worldwide,
meeting the rapidly expanding needs of life science and
healthcare organizations for data-driven decision making leading to
safer, more effective products.
Instem's portfolio of software solutions increases client productivity
by automating study-related
processes while offering the unique ability to generate
new knowledge through the extraction
and harmonization of actionable scientific information.
Instem supports over 400 clients through full service offices in the
United States, United Kingdom and China with additional locations in
India and a full service distributor based in Japan.
To learn more about Instem solutions and its mission, please visit www.instem.com
Meeting clients at the intersection of investment & return™.
[ Back To NFVZone's Homepage ]